Back

Laboratory of Genetic Diagnostic

Can geneticists help oncologists?

Not only hereditary diseases are determined using genetic research, during treatment of oncological patients we perform gene mutation researches, which are important during application of biological targeted therapy. It is a part of an individualised treatment, the possibility to choose the most suitable medicine for treatment of the patient.

The newest genetic analysis methods: a next generation sequencing and real-time PCR. Next-Generation Sequencing allows to perform multiple gene sequencing during one run and to determine the overall gene mutation or gene expression profile. Real-time PCR method allows detecting selected gene mutations precisely, sensitively and rapidly, it is important for the selection of targeted therapies and for predicting of the course of the disease. Cancer DNA and cancer cells, circulating in body fluids, are examined in the laboratory. Researches of BRCA1/2 and other gene mutations, which help to diagnose familial tumors, are performed. Over 40 thousand immunoassay tests are performed in the laboratory of tumor markers every year; the wide spectrum of examined tumor markers is implemented.

Performed research directions are related to search and detection of non-invasive biomarkers.

Main projects:

  • LMT SEN 09/2016 “Molecular tools for individualisation of long-term monitoring and treatment of prostate cancer.”
  • Study of kidney cancer molecular markers in patients' urine (ordered research of “Novartis Pharma Services”, sponsored by MITA).

Selected publications:

  1. Demidenko, Rita, Kristina Daniunaite, Arnas Bakavicius, Rasa Sabaliauskaite, Aiste Skeberdyte, Donatas Petroska, Arvydas Laurinavicius, Feliksas Jankevicius, Juozas R. Lazutka, and Sonata Jarmalaite. "Decreased expression of MT1E is a potential biomarker of prostate cancer progression." Oncotarget (2017).
  2. Stuopelyte, Kristina, Kristina Daniunaite, Arnas Bakavicius, Juozas R. Lazutka, Feliksas Jankevicius, and Sonata Jarmalaite. “The utility of urine-circulating miRNAs for detection of prostate cancer.” British Journal of Cancer 115.6 (2016): 707-15.
  3. Stuopelytė K, Daniūnaitė K, Jankevičius F, Jarmalaitė S. Detection of miRNAs in urine of prostate cancer patients. Medicina 52.2(2016):116-24.


Updated 2018-04-26 13:05